High-Risk IV Medications in Special Patient Populations
Critically ill patients are at risk for a higher frequency and severity of adverse drug events (ADEs), and special patient populations of the critically ill – requiring for instance individualized dosing due to non-average weight, hepatic or renal dysfunction, extracorporeal circulation devices, adv...
Συγγραφή απο Οργανισμό/Αρχή: | |
---|---|
Άλλοι συγγραφείς: | , |
Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
Γλώσσα: | English |
Έκδοση: |
London :
Springer London : Imprint: Springer,
2011.
|
Θέματα: | |
Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Anesthetic agents (general, inhaled, intravenous)
- Propofol, ketamine, etc
- Anti-infectives
- aminoglycosides, vancomycin, drotrecogin, amphotericin products
- inhaled agents
- Anticoagulants agents
- unfractionated heparin, low molecular weight heparins, fondaparinux, lepirudin, argatroban, bivalrudin, abciximab, eptifibatide, tirofiban
- Thrombolytics –reteplase, tenecteplase, streptokinase, urokinase, alteplase
- Cardiac Drugs
- Adrenergic agents
- dopamine, dobutamine, vasopressin, , nitroglycerin, nitroprusside epinephrine, norepinepherine, phenylepherine
- Adrenergic antagonists
- Propranolol, diltiazem, verapamil, esmolol, labetalol, clevidipine
- Antidyrrhthmics
- amiodarone, lidocaine, procainamide
- Inotropic agents
- milrinone, amrinone, isoproterenol, niseritide, digoxin
- Prostanoids
- Epoprostenol, iloprost, treprostenil
- Electrolytes
- Potassium, magnesium, sodium chloride (hypertonic), cardioplegic solutions
- Hypoglycemics
- Insulin and oral agents
- Neuromuscular blocking agents
- vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine
- Opioids (IV, oral)
- Remifentanyl, fentanyl , morphine, hydromorphone, meperidine
- Sedatives (IV, oral and transdermal)
- lorazepam, midazolam, diazepam, propofol, dexmedetomidine
- Information for Each Drug
- Propofol
- Normal
- Obese
- Renal Dysfunction
- CrCL
- Dialysis (HD, CRRT)
- Liver Dysfunction
- Recommendations for Safe Use.